z-logo
Premium
Trabeculectomy surgery augmented with intra‐Tenon injection of mitomycin C
Author(s) -
Lee Edward,
Doyle Eddie,
Jenkins Christopher
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2007.01147.x
Subject(s) - medicine , trabeculectomy , mitomycin c , ophthalmology , intraocular pressure , glaucoma , bleb (medicine) , glaucoma medication , glaucoma surgery , surgery , mortise and tenon , structural engineering , engineering
. Purpose:  To describe a novel approach to mitomycin C (MC) application during trabeculectomy surgery and to report the 1‐year results of surgery using this technique. Methods:  One hundred and eight consecutive trabeculectomies and phaco‐trabeculectomies using MC were performed by a single consultant surgeon, using a standardized technique. This technique involved injecting MC into the Tenon’s layer during the procedure, rather than applying it directly to the under‐surface of the conjunctiva. Results:  Preoperative mean intraocular pressure (IOP) was 23.6 ± 5.8mmHg. Mean IOP 12 months following surgery was 12.2 ± 3.9 mmHg. Seventy‐six eyes (70.3%) had an IOP less than 2/3 listing IOP at 12 months without the need for anti‐glaucoma medication. Ninety‐three eyes (86%) had an IOP <21 mmHg, 79 (73%) had an IOP <16 mmHg and 62 (57%) had an IOP <14 mmHg without anti‐glaucoma medication at 12 months. Transient complications included hyphaema, bleb leak and choroidal detachment in 14.8%, 5.6% and 15.7% of cases, respectively. Hypotony (defined as IOP <7 mmHg, excluding the first day postoperatively) was seen in 21.3% of cases. At 12 months, 21 eyes (19.4%) had cystic blebs and five (4.6%) had Tenon’s cysts with an IOP greater than 20 mmHg. Conclusion:  A novel means of applying intraoperative MC is described. The 12‐month outcome data show it to be an effective technique that compares favourably with others in the literature.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here